Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptevo Therapeutics

0.6748
-0.0168-2.43%
Post-market: 0.6740-0.0008-0.12%19:57 EDT
Volume:415.44K
Turnover:272.70K
Market Cap:2.18M
PE:-0.01
High:0.6916
Open:0.6600
Low:0.6220
Close:0.6916
Loading ...

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire
·
23 Apr

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire
·
22 Apr

Top Midday Gainers

MT Newswires Live
·
04 Apr

Aptevo Therapeutics Launches $2.1 Million Registered Direct Offering; Shares Rise

MT Newswires Live
·
03 Apr

Aptevo Therapeutics prices 1.76M shares at $1.19 in registered direct offering

TIPRANKS
·
03 Apr

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire
·
03 Apr

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

Benzinga
·
21 Mar

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live
·
21 Mar

Aptevo Therapeutics Reports 2 More Remissions in AML Trial

MT Newswires Live
·
20 Mar

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESS Newswire
·
20 Mar

Aptevo to Participate in March Conferences

ACCESS Newswire
·
06 Mar

Aptevo Therapeutics files $100M mixed securities shelf

TIPRANKS
·
15 Feb

Aptevo Therapeutics 22024 EPS $(87.38), Cash Position $8.7M

Benzinga
·
14 Feb

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

ACCESS Newswire
·
14 Feb

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

ACCESSWIRE
·
15 Jan

Aptevo Therapeutics (APVO) Receives a Buy from Roth MKM

TIPRANKS
·
21 Dec 2024

Aptevo Therapeutics Shares Slump After Warrant Exercised at a Discount

MT Newswires Live
·
13 Dec 2024

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

ACCESSWIRE
·
13 Dec 2024

Aptevo Therapeutics Shares Rally After Trial Results Show Complete Remission by Acute Myeloid Leukemia Patients

MT Newswires Live
·
12 Dec 2024

Aptevo Therapeutics trading halted, volatility trading pause

TIPRANKS
·
12 Dec 2024